Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold. During the shortages, federal law let pharmacies and outsourcing facilities make what were in effect copies of Wegovy, Ozempic, Zepbound and Mounjaro; since the shortages ended, the room to make them has shrunk.1,2
What is allowed now
FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, and the grace periods for compounders ended by May 2025.3 What remains is narrow:
- a state-licensed 503A pharmacy may compound for an individual patient on a prescription, when the product is not in effect a copy of an approved drug;
- a 503B outsourcing facility may not use bulk semaglutide, which is on neither the shortage list nor the 503B bulks list; on April 30, 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that list.4
FDA's own example of a copy is telling: a combination of semaglutide and vitamin B12 may still count as a copy when the strengths are within 10% of the approved products and the route is the same.3 Our page on compounded semaglutide explains the test in full.
What FDA has found
- Adverse events. By May 31, 2026, FDA had received 990 reports about compounded semaglutide and more than 730 about compounded tirzepatide, and says the true count is probably higher because 503A pharmacies are not required to report them.
- The wrong ingredient. Some products sold as semaglutide contain semaglutide sodium or semaglutide acetate, salts that are different active ingredients from the one in the approved drugs.
- False labels. Some labels name a real licensed pharmacy that did not make the product.
- Handling. FDA has received complaints of products arriving warm or with too few ice packs, and advises not using any injectable GLP-1 that arrives that way. A multi-dose vial should be used within 28 days of first use.
FDA, concerns with unapproved GLP-1 drugs, content current as of October 1, 2026.1
Dosing errors
Because a patient measures the dose from a vial, compounded products carry a particular risk of mistakes. FDA has alerted health care providers, compounders and patients to dosing errors with compounded semaglutide, some of which needed hospital care.5 A study of the National Poison Data System found 10,033 exposures to GLP-1 medicines of all kinds from 2012 to 2023, 6,920 of them after July 2021; most were unintentional dosing errors with mild stomach symptoms. The share treated in or referred to a health care facility rose from 23.0% to 33.5%.6
What cannot be compounded
Products sold as "research use only", and drugs still in trials such as retatrutide, cannot be lawfully compounded or sold for people.1 A search of DailyMed shows retatrutide listings from one company marked "Export only", which are not FDA approvals.7
Questions to ask about a compounded product
- Which pharmacy made it, and is that pharmacy licensed in my state? The name on the label should match a pharmacy that exists and says it made the product.
- What is the active ingredient? Semaglutide or tirzepatide, not a salt form.
- How was it shipped, and when was the vial first opened? Warm on arrival means do not use it; 28 days after first use means discard it.
Compiled from FDA's list of concerns.1
The choice today
The price gap that drove compounding has narrowed: the makers now sell self-pay versions, with Zepbound from $299 a month and the Wegovy tablet from $149. The Wegovy pen costs $349 a month after the first two fills, and Zepbound reaches $449 at its higher doses.8 Our page on GLP-1 costs without insurance compares every option.
Sources
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
- U.S. Food and Drug Administration. Compounding laws and policies. Content current as of December 17, 2024, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, April 30, 2026. fda.gov
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Content current as of July 26, 2024. fda.gov
- Miller J, Miller R, Varney SM, Han D. National poison center trends in GLP-1 receptor agonist exposures following FDA approval for weight loss. J Med Toxicol 2026;22:275-285. doi:10.1007/s13181-026-01121-z
- DailyMed, U.S. National Library of Medicine. Search for "retatrutide", 10 results, all from Guangzhou Yixin Cross-border E-commerce Co., Ltd., marketing status "Export only"; read November 20, 2026. dailymed.nlm.nih.gov
- Dose Insider. GLP-1 cost without insurance: every self-pay price compared. Prices read November 20, 2026, from the makers' self-pay pages. doseinsider.com
Related analyses
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy cost: what the pen and the pill cost with insurance, without it, and over a year
Zepbound cost: what you pay with insurance, without it, and over a year
Log which pharmacy filled each dose and how you felt, so problems are easy to trace.
Open Dose Insider